SAN DIEGO, July 13, 2015 /PRNewswire/ -- Sequenom
Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ:
SQNM), a life sciences company committed to enabling healthier
lives through the development of innovative products and services,
announced today the upcoming launch of the MaterniT™ GENOME
laboratory-developed test. This test is the first noninvasive
prenatal test (NIPT) to provide karyotype-level insight into fetal
chromosomal status prior to considering an invasive procedure. The
MaterniT GENOME test adds genome-wide identification of chromosomal
gains or losses greater than 7 megabases (Mb) in size to Sequenom
Laboratories' growing NIPT testing portfolio.
"While cell-free DNA screening has marked a significant
improvement in identifying pregnancies at risk for select
whole chromosome aneuploidies, there remain a number of significant
cytogenetic abnormalities that noninvasive prenatal testing has not
been able to identify," said Ronald
Wapner, M.D., Director of Reproductive Genetics at
Columbia University Medical
Center. "The ability to noninvasively detect subchromosomal
alterations 7 megabases or greater throughout the genome should
identify the majority of these changes that were previously
undetectable by NIPT."
The MaterniT GENOME test builds upon the industry leading
microdeletion performance demonstrated by Sequenom Laboratories
with the MaterniT21 PLUS laboratory-developed test, which was
recently highlighted in an article by Hume JH, et al, published in
the peer-reviewed journal Prenatal Diagnosis. Data
supporting the validation of the MaterniT GENOME test will be
presented at the 19th International Conference on
Prenatal Diagnosis and Treatment (sponsored by the International
Society of Prenatal Diagnosis and Therapy - ISPD) in Washington D.C., taking place July 12-15, 2015. The MaterniT GENOME test
will be available to physicians later this quarter.
"The MaterniT GENOME test fulfills our goal of delivering the
most relevant fetal genomic information noninvasively," said
William Welch, President and Chief
Executive Officer of Sequenom. "As pioneers and innovators in
noninvasive prenatal testing, we believe MaterniT GENOME represents
a safe, cost effective and meaningful breakthrough in NIPT,
supporting physicians in providing superior prenatal care for their
patients."
Sequenom Laboratories offers the most comprehensive portfolio of
noninvasive prenatal testing services, including the VisibiliT™ and
MaterniT21 PLUS tests, in addition to the new MaterniT GENOME
test.
Sequenom Laboratories Scientific Posters at ISPD
Sequenom Laboratories is featuring four posters at ISPD; three
posters showcasing recent research and clinical applications
associated with the MaterniT21 PLUS test, and one poster supporting
the new MaterniT GENOME test. The poster session will take place on
Tuesday, July 14, 2015, from 1:15 –
2:00 p.m. ET.
- Poster #P2-1 – Clinical experience of trisomy 16 and 22, and
microdeletion detection by noninvasive prenatal testing (NIPT)
- Poster #P2-2 – High volume clinical laboratory noninvasive
prenatal testing: results from >400,000 patients
- Poster #P2-8 – Leveraging targeted sequencing of paired
homologs for noninvasive detection of fetal aneuploidies
- Poster #P2-37 – Karyotype-level noninvasive prenatal testing by
sequencing of circulating cell-free DNA from maternal plasma
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is
committed to enabling healthier lives through the development of
innovative products and services. The Company serves patients and
physicians by providing early patient management information. To
learn how Sequenom is interpreting the genome to improve your life,
visit www.sequenom.com.
About Sequenom Laboratories
Sequenom
Laboratories™, a CAP-accredited and
CLIA-certified molecular diagnostics laboratory, has developed a
broad range of laboratory-developed tests, with a focus principally
on prenatal care. Branded under the names
HerediT® CF, HerediT®
UNIVERSAL, VisibiliT™,
MaterniT21® PLUS, MaterniT™ GENOME,
and NextView™, these molecular genetic
laboratory-developed tests provide early patient management
information for obstetricians, geneticists, genetic counselors and
maternal fetal medicine specialists. Sequenom Laboratories is
changing the landscape in genetic diagnostics using proprietary
cutting-edge technologies. Visit www.laboratories.sequenom.com and
follow @SequenomLabs.
SEQUENOM®, Sequenom Laboratories™,
HerediT® CF, HerediT® UNIVERSAL,
VisibiliT™, MaterniT21® PLUS,
MaterniT™ GENOME, and NextView™, are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services and the ability to identify
significant cytogenetic abnormalities through identification of
subchromosomal alterations 7 megabases or greater throughout the
genome. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Risks are described more fully in the Company's filings with the
Securities and Exchange Commission, including without limitation
the Company's most recent Quarterly Report on Form 10-Q and other
documents subsequently filed with or furnished to the Securities
and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
![SEQUENOM logo SEQUENOM logo](http://photos.prnewswire.com/prnvar/20040415/SQNMLOGO)
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-launches-maternit-genome-300111863.html
SOURCE Sequenom, Inc.